663 results on '"Peipp, Matthias"'
Search Results
2. Optimised protocols for RNA extraction from a broad taxonomic range of algae
3. Targeted siRNA nanocarrier: a platform technology for cancer treatment
4. The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis
5. Affinity Maturation of the Natural Ligand (B7-H6) for Natural Cytotoxicity Receptor NKp30 by Yeast Surface Display
6. Rekrutierung von Natürlichen Killerzellen durch optimierte Immunliganden
7. Engineering an inducible leukemia-associated fusion protein enables large-scale ex vivo production of functional human phagocytes
8. CD20 expression regulates CD37 levels in B-cell lymphoma – implications for immunotherapies
9. Combining Cellular Immunization and Phage Display Screening Results in Novel, FcγRI-Specific Antibodies
10. Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis
11. Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL
12. Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia
13. Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
14. Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade
15. Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3
16. The selection of variable regions affects effector mechanisms of IgA antibodies against CD20
17. CD20 expression regulates CD37 levels in B-cell lymphoma: implications for immunotherapies.
18. 424 Adoptive cell therapy with cytokine-induces killer cells armed with immunotools against Her-2 expressing breast cancer
19. 1005 BiXAb® MAIT Engagers: solving the problems of classical T-cell engagers in the treatment of solid tumors
20. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells
21. P-199 Novel antibodies identified by phage display induce direct myeloma cell death
22. P-198 Impact of blocking the CD47 axis on phagocytosis of myeloma cells treated with CD38 antibodies and proteasome inhibitors
23. Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition
24. Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma
25. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
26. Abstract 2954: MAIT engagers: An efficacious novel modality in the field of T-cell engagers for the treatment of solid tumors
27. Data from Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies
28. Supplementary Figures 1-3 and Table1 from Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies
29. Data from The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity In Vitro and In Vivo
30. Supplementary Figures from The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity In Vitro and In Vivo
31. An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts
32. Novel NKG2D-directed bispecific antibodies enhance antibodymediated killing of malignant B cells by NK cells and T cells.
33. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients
34. Data from Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
35. Supplementary Figure Legends from Novel Bispecific Antibodies Increase γδ T-Cell Cytotoxicity against Pancreatic Cancer Cells
36. Data from An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo
37. Supplementary Figure 2 from Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
38. Supplementary Legends of Tables 1-2, Figures 1-5 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
39. Data from Novel Bispecific Antibodies Increase γδ T-Cell Cytotoxicity against Pancreatic Cancer Cells
40. Supplementary Figure 3 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
41. Supplementary Figure 2 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
42. Supplementary Figure 1 from Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
43. Supplementary Figure 3 from Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
44. Supplementary Methods from Novel Bispecific Antibodies Increase γδ T-Cell Cytotoxicity against Pancreatic Cancer Cells
45. Supplementary Figure 5 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
46. Supplementary Figure 1 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
47. Supplementary Table 1 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
48. Supplementary Table 2 from Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
49. Supplementary Table 1 from An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo
50. Supplementary Table 3 from An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.